Figure 7.

cGAS and STING are essential for Svg3 to potentiate ICB tumor immunotherapy in mice

(A) B16F10 tumor growth curves in cGas^−/− mice treated with liposomal Svg3, with liposomal 2′3′-cGAMP as a control, alone or combined with αPD-1. Svg3, but not 2′3′-cGAMP, lost the ability to potentiate the tumor therapeutic efficacy of αPD-1. p values were determined by t test on day 19 (2′3′-cGAMP + αPD-1 vs. PBS) and day 22 (αPD-1 or Svg3 + αPD-1 vs. 2′3′-cGAMP + αPD-1). (B) B16F10 tumor grow curves in Sting^gt/gt mice treated as above. Neither Svg3 nor 2′3′-cGAMP significantly potentiated the tumor therapeutic efficacy of αPD-1. Arrows mark treatments. Liposomal Svg3 and 2′3′-cGAMP, i.t., 5 × 3 nmol; αPD-1, i.p., 5 × 100 μg. Data: mean ± SEM. p values were determined by t test on day 19. ns, not significant; p > 0.05, ∗p < 0.05, ∗∗∗p < 0.001.